Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Multicenter Study of Exemestane With and Without SNDX-275 in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer, Progressing on Treatment With a Non-Steroidal Aromatase Inhibitor

NCT00676663 is registered in ClinicalTrials.gov with Syndax Pharmaceuticals as lead sponsor.

NCT NCT00676663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00676663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Multicenter Study of Exemestane With and Without SNDX-275 in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer, Progressing on Treatment With a Non-Steroidal Aromatase Inhibitor
Lead sponsor
Syndax Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
June 13, 2008
Completion date
November 26, 2012
Enrollment
130 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast cancer, estrogen receptor-positive, er+ breast cancer, estrogen receptor-positive breast cancer